A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
Status:
Completed
Trial end date:
2023-09-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of BMS-986419 on the pharmacokinetics (PK)
of single doses of caffeine (CYP1A2 substrate), bupropion (CYP2B6 substrate), midazolam
(CYP3A4 substrate), flurbiprofen (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and
fexofenadine (P-gp substrate), in healthy participants.